S Yuexing Chang: Gastric disease vaccine opens up new space

March 8, S Yuexing Chang (Yueyang Xing Chang Petrochemical Co., Ltd.) announced that the company's holding subsidiary Chongqing Kangsanitary Technology Co., Ltdreceived on the 5th of this month, China'sPharmaceutical seditonBiologics Inspection Institute", "oral recombinant Helicobacter pylori vaccine Phase III clinical trial summary report", the letter said, "oral recombinant Helicobacter pylori vaccine PHASE III clinical trial summary report" has been completedThe problem of rooting out stomach problems is no longerfor china's tens of millions or even hundreds of millions of gastric patients, they may not know what Helicobacter pylori (Hp) is, the difficult to cure the "old stomach disease" and what does it have to do with it?Helicobacter pylori is the most common and globally infected human pathogen, with two-thirds of the world's population infected with the bacteria, a medical professional saidHelicobacter pylori is a well-recognized cause of ulcers and is associated with stomach cancerThe World Health Organization lists Helicobacter pylori as the only bacterial type I carcinogenGastric disease is also one of the most common digestivediseasesin ChinaNearly 10% of our social population suffer from stomach ulcers and nearly 30% suffer from gastritisThe Helicobacter pylori vaccine PHASE III Report shows that the total protection rate of helicobacter pylori vaccine (gastric disease vaccine) for prevention of infection is 72.10%, and there is no statistical difference in the protection rate of one-year prevention of Hp infection in different townships, different genders and different ages; The advent of gastric disease vaccines is undoubtedly a boon for many patients with the stomach disease5
years of technical barriers
due to the "Helicobacter pylori vaccine III report" has been completed, to the State Drug Administration to declare the new drug is a matter of time 3 to 6 months time is expected to be successful application Once the application is successful, it will be covered by a five-year protection period Relevant information shows that in November 2000, S Yuexing Chang, Chinese Pla Third Military Medical University and Chongqing Yangchun Biotech Co., Ltd jointly funded the formation of Chongqing Kangwei (S Yuexing Chang Holding 57.63%), to cooperate in the study of the national Class I new drug oral recombinant Helicobacter pylori vaccine Chongqing Kangwei developed gastric disease vaccine belongs to the national Class I new biological products, at home and abroad have no similar products sold, is the world's first to enter and complete phase III clinical gastric disease vaccine According to the provisions of the Measures for the of Drug Registration, the vaccine, if it obtains a new drug certificate, will enjoy the state's policy of protection for class I new drugs: from the date of entry into the monitoring period of the new drug (5 years from the date of approval), no applications for registration of the same varieties of other applicants will be accepted 10 00 billion yuan market urgently need to develop
the Helicobacter pylori vaccine market has long been concerned by an analyst told reporters that China's current market demand for gastric disease vaccine is expected to reach 1 billion yuan, mainly from the three major market segments The first is the market for new and young children According to relevant information, China's annual birth of about 18 million babies , there is a huge children immunization market At present, the total population of pre-school children is about 150 million The second is the primary and secondary school market The number of primary and secondary school students in China is currently about 150 million The third is the stomach disease market The number of people infected with Helicobacter pylori in China is about 500-700 million, taking into account people's cognitive level and health care awareness has a gradual improvement of the process, its potential vaccine demand is expected to reach 500 million people However, one pharmaceutical marketer cautioned that it would take time from application to mass production, and that the success of a new drug depended not only on technology but also on market approval Establishing effective sales channels is often the key to new drugs truly gaining a foothold in the country In terms of vaccines, Chinese pharmaceutical companies have little sales experience There is also a greater resistance from the habit of Chinese "It's no wonder if you have a doctor," but it's hard to say whether you can do a "disease-free vaccine" The cultivation of this market requires more time (reproduced from China Medical Daily)